Your browser doesn't support javascript.
loading
High-Throughput Screen for Inhibitors of Klebsiella pneumoniae Virulence Using a Tetrahymena pyriformis Co-Culture Surrogate Host Model.
Woods, Angela L; Parker, David; Glick, Meir M; Peng, Yunshan; Lenoir, Francois; Mulligan, Evan; Yu, Vincent; Piizzi, Grazia; Lister, Troy; Lilly, Maria-Dawn; Dzink-Fox, JoAnn; Jansen, Johanna M; Ryder, Neil S; Dean, Charles R; Smith, Thomas M.
Afiliação
  • Woods AL; Infectious Diseases, Novartis Institutes for Biomedical Research Inc, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States.
  • Parker D; Global Discovery Chemistry, Novartis Institutes for Biomedical Research Inc, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States.
  • Glick MM; Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research Inc, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States.
  • Peng Y; Global Discovery Chemistry, Novartis Institutes for Biomedical Research Inc, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States.
  • Lenoir F; Global Discovery Chemistry, Novartis Institutes for Biomedical Research Inc, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States.
  • Mulligan E; Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research Inc, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States.
  • Yu V; Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research Inc, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States.
  • Piizzi G; Global Discovery Chemistry, Novartis Institutes for Biomedical Research Inc, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States.
  • Lister T; Global Discovery Chemistry, Novartis Institutes for Biomedical Research Inc, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States.
  • Lilly MD; Infectious Diseases, Novartis Institutes for Biomedical Research Inc, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States.
  • Dzink-Fox J; Infectious Diseases, Novartis Institutes for Biomedical Research Inc, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States.
  • Jansen JM; Global Discovery Chemistry, Novartis Institutes for Biomedical Research Inc, Emeryville California 94608-2916, United States.
  • Ryder NS; Infectious Diseases, Novartis Institutes for Biomedical Research Inc, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States.
  • Dean CR; Infectious Diseases, Novartis Institutes for Biomedical Research Inc, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States.
  • Smith TM; Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research Inc, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States.
ACS Omega ; 7(6): 5401-5414, 2022 Feb 15.
Article em En | MEDLINE | ID: mdl-35187355
ABSTRACT
The continuing emergence of antibacterial resistance reduces the effectiveness of antibiotics and drives an ongoing search for effective replacements. Screening compound libraries for antibacterial activity in standard growth media has been extensively explored and may be showing diminishing returns. Inhibition of bacterial targets that are selectively important under in vivo (infection) conditions and, therefore, would be missed by conventional in vitro screens might be an alternative. Surrogate host models of infection, however, are often not suitable for high-throughput screens. Here, we adapted a medium-throughput Tetrahymena pyriformis surrogate host model that was successfully used to identify inhibitors of a hyperviscous Klebsiella pneumoniae strain to a high-throughput format and screened circa 1.2 million compounds. The screen was robust and identified confirmed hits from different chemical classes with potent inhibition of K. pneumoniae growth in the presence of T. pyriformis that lacked any appreciable direct antibacterial activity. Several of these appeared to inhibit capsule/mucoidy, which are key virulence factors in hypervirulent K. pneumoniae. A weakly antibacterial inhibitor of LpxC (essential for the synthesis of the lipid A moiety of lipopolysaccharides) also appeared to be more active in the presence of T. pyriformis, which is consistent with the role of LPS in virulence as well as viability in K. pneumoniae.

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: ACS Omega Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: ACS Omega Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos